HysterectomyNCT07876037
Oral Contraceptive Pills on Woman With Post Hysterectomy Ovarian Cyst
A study testing Group 2 (Study group) in people with Hysterectomy and Ovarian Cyst, run by Tanta University at 1 site in Egypt.
Trial summary
To evaluate the therapeutic effect of combined oral contraceptive pills in women with benign post-hysterectomy ovarian cysts. Read more about this study
- Who is it for?
- Ages 40 years and older, women only
- Conditions the study is for
- Hysterectomy, Ovarian Cyst, Contraceptive
- What is being tested?
- Group 2 (Study group)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteEgypt
- Study dates
- 30 Aug 2024to 30 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age ≥ 40 years old,
- patient with post-hysterectomy ovarian cyst with the simple ovarian cyst with no septation or solid cyst,
- woman with preoperative normal ovaries.
Who cannot join
- data of previous hysterectomy was deficient,
- infected cyst,
- suspicious cyst.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Therapeutic Effect of Oral Contraceptive Pills on Woman With Post Hysterectomy Ovarian Cyst
To evaluate the therapeutic effect of combined oral contraceptive pills in women with benign post-hysterectomy ovarian cysts.
Read the detailed description
Hysterectomy is one of the most frequently performed gynecological procedures worldwide, predominantly for benign uterine disorders . Although ovarian preservation avoids the consequences of premature menopause, ovarian cysts may subsequently develop and occasionally require treatment. Most simple cysts resolve spontaneously; however, persistent or symptomatic lesions often necessitate therapeutic intervention . Combined oral contraceptive pills have been proposed as a conservative option by suppressing ovarian activity, yet evidence regarding their effectiveness in women with post-hysterectomy ovarian cysts remains limited and inconsistent . Therefore, this randomized controlled study was designed to evaluate the therapeutic effect of combined oral contraceptive pills on benign post-hysterectomy ovarian cysts .
- Conditions
- Hysterectomy, Ovarian Cyst, Contraceptive
- Being tested
- Group 1 (Control group), Group 2 (Study group)
- Keywords
- Oral Contraceptive Pills, Woman, Ovarian Cyst, Hysterectomy
- Medical subject headings
- Ovarian Cysts
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group 1 (Control group)Drug
Women received folic acid treatment (placebo effect).
Group 2 (Study group)Drug
Women received combined oral contraceptive pills (COCP) for 3 months (continuous daily) and then follow up after 6 months.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 (Control group) | Placebo comparator | Women received folic acid treatment (placebo effect). Receives: Drug: Group 1 (Control group) |
| Group 2 (Study group) | Experimental | Women received combined oral contraceptive pills for 3 months (continuous daily) and then follow up after 6 months. Receives: Drug: Group 2 (Study group) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of cyst regression
Measured: at 3 months or 6 months
Secondary outcomes (1)
occurrence of complications
Measured: at 3 months or 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2026
- Study start30 Aug 2024
- Primary completion30 Aug 2025
- Study completion30 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HysterectomyStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Doaa Karam Abd Elrasoul Abd Elsamad, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07876037
- Sponsor's protocol ID
- 36264MS638/7/24
- Status last verified
- Aug 2024
- First submitted
- 3 Oct 2026
- Last updated
- 15 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: It will be available if it needed
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Therapeutic Effect of Oral Contraceptive Pills on Woman With Post Hysterectomy Ovarian Cyst
- ClinicalTrials.gov ID
- NCT07876037
- Acronym / sponsor ID
- 36264MS638/7/24
- Conditions
- Hysterectomy, Ovarian Cyst, Contraceptive
- Keywords
- Oral Contraceptive Pills, Woman, Ovarian Cyst, Hysterectomy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 30 Aug 2024 (actual)
- Primary completion
- 30 Aug 2025 (actual)
- Study completion
- 30 Aug 2025 (actual)
- First posted
- 15 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the therapeutic effect of combined oral contraceptive pills in women with benign post-hysterectomy ovarian cysts.
Detailed description
Hysterectomy is one of the most frequently performed gynecological procedures worldwide, predominantly for benign uterine disorders . Although ovarian preservation avoids the consequences of premature menopause, ovarian cysts may subsequently develop and occasionally require treatment. Most simple cysts resolve spontaneously; however, persistent or symptomatic lesions often necessitate therapeutic intervention . Combined oral contraceptive pills have been proposed as a conservative option by suppressing ovarian activity, yet evidence regarding their effectiveness in women with post-hysterectomy ovarian cysts remains limited and inconsistent . Therefore, this randomized controlled study was designed to evaluate the therapeutic effect of combined oral contraceptive pills on benign post-hysterectomy ovarian cysts .
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1 (Control group) | Placebo comparator | Drug: Group 1 (Control group)Women received folic acid treatment (placebo effect). |
| Group 2 (Study group) | Experimental | Drug: Group 2 (Study group)Women received combined oral contraceptive pills for 3 months (continuous daily) and then follow up after 6 months. |
Who may qualify
- Ages
- 40 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- age ≥ 40 years old,
- patient with post-hysterectomy ovarian cyst with the simple ovarian cyst with no septation or solid cyst,
- woman with preoperative normal ovaries.
Key exclusion criteria (3 listed)
- data of previous hysterectomy was deficient,
- infected cyst,
- suspicious cyst.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group 1 (Control group)Women received folic acid treatment (placebo effect). | Drug | Group 1 (Control group) |
| Group 2 (Study group)Women received combined oral contraceptive pills (COCP) for 3 months (continuous daily) and then follow up after 6 months. | Drug | Group 2 (Study group) |
Primary outcome
Incidence of cyst regression
Time frame: at 3 months or 6 months
1 secondary outcome
occurrence of complications
Time frame: at 3 months or 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
- Individual participant dataSharing planned: Yes. It will be available if it needed
Related trials for Hysterectomy
Recruiting
Implementation of a Pain Management Plan in Major Open Abdominal Surgeries.
Abdomen Cancer, Pancreas Adenocarcinoma (MSI-H)
Not yet recruiting
COMPARISON OF THE POSTOPERATIVE ANALGESIC EFFECTS OF ULTRASOUND-GUIDED QUADRO-ILIAC PLANE AND TRANSVERSUS ABDOMINIS PLANE BLOCKS IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY
Postoperative Pain Following Total Laparoscopic Hysterectomy
Active, not recruitingPhase 2
Intravenous Ibuprofen Postoperative Analgesia After Abdominal Hysterectomy
Post Operative Analgesia
RecruitingObservational study
Predictors of Success and Failure of v-NOTES Hysterectomy for Large and Very Large Uteri
Uterine Fibroids, Hysterectomy
Active, not recruiting
Clinical Assessment - HominisTM Surgical System
Hysterectomy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Group 2 (Study group) in people with Hysterectomy and Ovarian Cyst, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of cyst regression (time frame: at 3 months or 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.